VRTX Stock Recent News
VRTX LATEST HEADLINES
Vertex's dominance in the cystic fibrosis drug market could be challenged. Even in the worst-case scenario, its challenger's products won't be launched soon.
Vertex Pharmaceuticals has built a billion-dollar cystic fibrosis business over time. But the company today may be preparing for a new era of growth, thanks to the strength of its pipeline.
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $490.80, denoting a +0.1% change from the preceding trading day.
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $495.91, indicating a +0.88% shift from the previous trading day.
Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options.
Problems with the central nervous system are the second leading cause of death globally, the World Health Organization determined in 2022. One reason for this situation is that it's extremely difficult to develop effective treatments for these disorders because of the complexity of the CNS, European biotech news website Labiotech reported last year.
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $490.85, signifying a +0.43% move from its prior day's close.
Vertex Pharmaceuticals and Axsome Therapeutics are moving toward key regulatory approvals. Thanks to solid tailwinds, both biotechs should handsomely reward investors over the long run.
Vertex's stock has risen 18% since last December, matching the SPY index, bolstered by promising Phase 2 data for VX-548 in diabetic peripheral neuropathy. Vertex is expanding into gene therapies and other rare disease treatments, recently acquiring Alpine Immune Sciences for $4.9 billion to enhance its rare disease pipeline. Q1 2024 earnings exceeded expectations with a 13% revenue increase, primarily from their cystic fibrosis drug, Trikafta/Kaftrio.